U.S. License Holder:
Boehringer Ingelheim Pharmaceuticals Inc.
Date of License:
September-01-2022
Last Update:
Mar-08-2024
FDA-Approved Indications
SPEVIGO (spesolimab-sbzo) is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis flares in adults.